Challenges in management of older patients with chronic myeloid leukemia

References

• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
   PubMed Web of Science ®Google Scholar
• Cancer stat facts: leukemia—chronic myeloid leukemia (CML) [cited 2024 Jan 24]. Available from: https://seer.cancer.gov/statfacts/html/cmyl.html
   Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map. Blood Rev. 2020;42:100706. doi:10.1016/j.blre.2020.100706
   PubMed Web of Science ®Google Scholar
• Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123–3127. doi:10.1002/cncr.26679
   PubMed Web of Science ®Google Scholar
• GLEEVEC (imatinib mesylate) tablets, for oral use. East Hanover (NJ): Novartis Pharmaceuticals Corporation [package insert]. [cited 2024 Jan 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf
   Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037. doi:10.1056/NEJM200104053441401
   PubMed Web of Science ®Google Scholar
• Bower H, Björkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857. doi:10.1200/JCO.2015.66.2866
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–2270. doi:10.1056/NEJMoa1002315
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–2259. doi:10.1056/NEJMoa0912614
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–237. doi:10.1200/JCO.2017.74.7162
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–1796. doi:10.1056/NEJMoa1306494
   PubMed Web of Science ®Google Scholar
• Rea D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031–2041. doi:10.1182/blood.2020009984
   PubMed Web of Science ®Google Scholar
• SPRYCEL® (dasatinib) tablet for oral use. Princeton (NJ): Bristol-Myers Squibb Company [package insert]. [cited 2024 Jan 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf
   Google Scholar
• TASIGNA® (nilotinib) capsules. East Hanover (NJ): Novartis Pharmaceuticals Corporation [package insert]. [cited 2024 Jan 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf
   Google Scholar
• BOSULIF® (bosutinib) tablets, for oral use. New York (NY): Pfizer [package insert]. [cited 2024 Jan 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf
   Google Scholar
• ICLUSIG® (ponatinib) tablets for oral use. Cambridge (MA): ARIAD Pharmaceuticals, Inc. [package insert]. [cited 2023 Oct 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf
   Google Scholar
• SCEMBLIX® (asciminib) tablets, for oral use. East Hanover (NJ): Novartis Pharmaceuticals Corporation [package insert]. [cited 2024 Jan 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf
   Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927. doi:10.1056/NEJMoa1609324
   PubMed Web of Science ®Google Scholar
• Sogawa R, Kimura S, Yakabe R, et al. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. Int J Clin Oncol. 2018;23(5):974–979. doi:10.1007/s10147-018-1275-6
   PubMed Web of Science ®Google Scholar
• Lou J, Huang J, Wang Z, et al. Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey. Patient Prefer Adherence. 2018;12:1025–1032. doi:10.2147/PPA.S163393
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN guidelines^®) for chronic myeloid leukemia version 1.2024. National Comprehensive Cancer Network, Inc.; 2023. https://www.nccn.org/home
   Google Scholar
• Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2009;23(3):602–604. doi:10.1038/leu.2008.245
   PubMed Web of Science ®Google Scholar
• Wang N, Yin J, You N, et al. Predictors of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Blood. 2020;136(Supplement 1):12–12. doi:10.1182/blood-2020-139005
   Google Scholar
• Winn AN, Keating NL, Dusetzina SB. Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia. J Clin Oncol. 2016;34(36):4323–4328. doi:10.1200/JCO.2016.67.4184
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Zeidan AM, et al. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Adv. 2023;7(13):3213–3224. doi:10.1182/bloodadvances.2022009074
   PubMed Web of Science ®Google Scholar
• Shallis RM, Podoltsev N. What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly? Expert Opin Pharmacother. 2019;20(10):1169–1173. doi:10.1080/14656566.2019.1599357
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Gugliotta G, Baccarani M, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2015;26(1):185–192. doi:10.1093/annonc/mdu490
   PubMed Web of Science ®Google Scholar
• Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56. doi:10.1038/leu.2015.261
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004. doi:10.1056/NEJMoa022457
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-Naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340. doi:10.1200/JCO.2015.64.8899
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–453. doi:10.1038/s41375-020-01111-2
   PubMed Web of Science ®Google Scholar
• Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825–1833. doi:10.1038/s41375-022-01589-y
   PubMed Web of Science ®Google Scholar
• Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612–621. doi:10.1016/S1470-2045(16)00080-2
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Réa D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617–626. doi:10.1038/s41375-023-01829-9
   PubMed Web of Science ®Google Scholar
• Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108(5):1478–1484. doi:10.1182/blood-2006-02-001495
   PubMed Web of Science ®Google Scholar
• Sokal JE, Baccarani M, Russo D, et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25(1):49–61.
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing committee for the collaborative CML prognostic factors project group. J Natl Cancer Inst. 1998;90(11):850–858. doi:10.1093/jnci/90.11.850
   PubMedGoogle Scholar
• Latagliata R, Breccia M, Carmosino I, et al. “Real-life” results of front-line treatment with imatinib in older patients (>/=65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res. 2010;34(11):1472–1475. doi:10.1016/j.leukres.2010.07.001
   PubMed Web of Science ®Google Scholar
• Rosti G, Iacobucci I, Bassi S, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica. 2007;92(1):101–105. doi:10.3324/haematol.10239
   PubMed Web of Science ®Google Scholar
• Cortes JE. A second-generation TKI should always be used as initial therapy for CML. Blood Adv. 2018;2(24):3653–3655. doi:10.1182/bloodadvances.2018018655
   PubMed Web of Science ®Google Scholar
• Stagno F, Breccia M, Annunziata M, et al. Long term follow-up of frontline dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. Acta Oncol. 2021;60(11):1527–1533. doi:10.1080/0284186X.2021.1971292
   PubMed Web of Science ®Google Scholar
• Amrein PC. Low-dose dasatinib: when less can be more. Lancet Haematol. 2021;8(12):e867–e868. doi:10.1016/S2352-3026(21)00342-2
   PubMedGoogle Scholar
• Luciano L, Latagliata R, Gugliotta G, et al. Efficacy and safety of nilotinib as frontline treatment in elderly (>65 years) chronic myeloid leukemia patients outside clinical trials. Ann Hematol. 2023;102(6):1375–1382. doi:10.1007/s00277-023-05159-9
   PubMed Web of Science ®Google Scholar
• Lipton JH, Le Coutre P, Wang J, et al. Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis. Blood. 2008;112(11):3233–3233. doi:10.1182/blood.V112.11.3233.3233
   Web of Science ®Google Scholar
• Latagliata R, Attolico I, Trawinska MM, et al. Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors. Hematol Oncol. 2021;39(3):401–408. doi:10.1002/hon.2851
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Bewersdorf JP, et al. Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Ther Adv Hematol. 2021;12:20406207211043404. doi:10.1177/20406207211043404
   Web of Science ®Google Scholar
• Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138(21):2042–2050. doi:10.1182/blood.2021012082
   PubMed Web of Science ®Google Scholar
• Cortes JE, Deininger MW, Lomaia E, et al. Three-Year update from the optic trial: a dose-Optimization study of 3 starting doses of ponatinib. Blood. 2022;140(Supplement 1):1495–1497. doi:10.1182/blood-2022-157822
   Google Scholar
• Mela Osorio MJ, Moiraghi B, Osycka MV, et al. Long-Term follow-up in patients with chronic myeloid leukemia treated with ponatinib in a real-world cohort: safety and efficacy analysis. Clin Lymphoma Myeloma Leuk. 2024;24(3):158-164. doi:10.1016/j.clml.2023.10.008
   PubMedGoogle Scholar
• Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315–2326. doi:10.1056/NEJMoa1902328
   PubMed Web of Science ®Google Scholar
• Mauro M, Minami Y, Hochhaus A, et al. Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ascembl, a phase 3 study of ASC Vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): an end of study treatment (EOS Tx) update, including results from switch population. Blood. 2023;142(Supplement 1):4536–4536. doi:10.1182/blood-2023-186854
   Google Scholar
• Vener C, Banzi R, Ambrogi F, et al. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv. 2020;4(12):2723–2735. doi:10.1182/bloodadvances.2019001329
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388. doi:10.1200/JCO.2009.26.3087
   PubMed Web of Science ®Google Scholar
• Mori S, Vagge E, Le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910–914. doi:10.1002/ajh.24120
   PubMed Web of Science ®Google Scholar
• Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61(3):650–659. doi:10.1080/10428194.2019.1675879
   PubMed Web of Science ®Google Scholar
• Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–757. doi:10.1016/S1470-2045(18)30192-X
   PubMed Web of Science ®Google Scholar
• Bidikian A, Jabbour E, Issa GC, et al. Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor. Am J Hematol. 2023;98(4):639–644. doi:10.1002/ajh.26836
   PubMed Web of Science ®Google Scholar
• Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon and STI571 (IRIS). Blood. 2010;116(19):3758–3765. doi:10.1182/blood-2010-03-273979
   PubMed Web of Science ®Google Scholar
• Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126(1):42–49. doi:10.1182/blood-2015-01-617993
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Boddu PC, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019;3(6):851–861. doi:10.1182/bloodadvances.2018025874
   PubMed Web of Science ®Google Scholar
• Cortes J. How to manage CML patients with comorbidities. Blood. 2020;136(22):2507–2512. doi:10.1182/blood.2020006911
   PubMed Web of Science ®Google Scholar
• Jabbour E, Makenbaeva D, Lingohr-Smith M, et al. Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on national comprehensive network treatment guidelines. Clin Lymphoma Myeloma Leuk. 2015;15(12):797–802. doi:10.1016/j.clml.2015.09.008
   PubMed Web of Science ®Google Scholar
• Ono T, Takahashi N, Kizaki M, et al. Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML. Cancer Sci. 2023;114(3):995–1006. doi:10.1111/cas.15642
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Cortes JE, Zyczynski T, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019;94(1):46–54. doi:10.1002/ajh.25306
   PubMed Web of Science ®Google Scholar
• Veltmaat L, Cortes J. Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors. Blood. 2024;143(10):858–865. doi:10.1182/blood.2023022403
   PubMedGoogle Scholar
• Douxfils J, Haguet H, Mullier F, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival. JAMA Oncol. 2016;2(5):625–632. doi:10.1001/jamaoncol.2015.5932
   PubMed Web of Science ®Google Scholar
• Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–2137. doi:10.1161/CIRCULATIONAHA.111.079921
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494–500. doi:10.1182/blood-2013-06-511592
   PubMed Web of Science ®Google Scholar
• Hughes TP, Laneuville P, Rousselot P, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2019;104(1):93–101. doi:10.3324/haematol.2018.188987
   PubMed Web of Science ®Google Scholar
• Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310–1315. doi:10.1038/leu.2013.69
   PubMed Web of Science ®Google Scholar
• Valent P, Hadzijusufovic E, Schernthaner GH, et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015;125(6):901–906. doi:10.1182/blood-2014-09-594432
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393–404. doi:10.1182/blood-2016-09-739086
   PubMed Web of Science ®Google Scholar
• Perez-Lamas L, Luna A, Boque C, et al. Toxicity of asciminib in real clinical practice; analysis of side effects and cross-intolerance with tyrosine kinase inhibitors. Blood. 2022;140(Supplement 1):3925–3928. doi:10.1182/blood-2022-167453
   Google Scholar
• García Gutiérrez JV, Radich JP, Hochhaus A, et al. Efficacy and safety of front-line nilotinib treatment and discontinuation in older patients (≥65 years) with chronic myeloid leukemia in chronic phase who have achieved MR4.5: results from ENESTfreedom. Blood. 2020;136(Supplement 1):7–8. doi:10.1182/blood-2020-137388
   Google Scholar
• Ohnishi K, Nakaseko C, Takeuchi J, et al. Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci. 2012;103(6):1071–1078. doi:10.1111/j.1349-7006.2012.02253.x
   PubMed Web of Science ®Google Scholar
• Cervantes F, Correa J-G, Pérez I, et al. Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Ann Hematol. 2017;96(1):81–85. doi:10.1007/s00277-016-2839-z
   PubMed Web of Science ®Google Scholar
• Jabbour E, Sasaki K, Haddad FG, et al. Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis. Am J Hematol. 2022;97(11):1413–1418. doi:10.1002/ajh.26689
   PubMed Web of Science ®Google Scholar
• Gener-Ricos G, Haddad FG, Sasaki K, et al. Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results. Clin Lymphoma Myeloma Leuk. 2023;23(10):742–748. doi:10.1016/j.clml.2023.05.009
   PubMed Web of Science ®Google Scholar
• Murai K, Ureshino H, Kumagai T, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8(12):e902–e911. doi:10.1016/S2352-3026(21)00333-1
   PubMed Web of Science ®Google Scholar
• Itamura H, Kubota Y, Shindo T, et al. Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg. Clin Lymphoma Myeloma Leuk. 2017;17(6):370–374. doi:10.1016/j.clml.2017.02.023
   PubMed Web of Science ®Google Scholar
• Claudiani S, Apperley JF, Szydlo R, et al. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol. 2021;193(2):346–355. doi:10.1111/bjh.17286
   PubMed Web of Science ®Google Scholar
• Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6(7):e375–e383. doi:10.1016/S2352-3026(19)30094-8
   PubMed Web of Science ®Google Scholar
• Rea D, Cayuela J-M, Dulucq S, et al. Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED). Blood. 2017;130(Supplement 1):318.
   Google Scholar
• Breccia M, Abruzzese E, Stagno F, et al. First interim analysis of the Italian Dante study: de-escalation before treatment-free remission in patients with chronic myeloid leukemia treated with first-line nilotinib. Blood. 2021;138(Supplement 1):1474–1474. doi:10.1182/blood-2021-145411
   Google Scholar
• Ureshino H, Takahashi N, Ikezoe T, et al. Lower-initiating dose of bosutinib for resistant or intolerant to prior therapy chronic myeloid leukemia patients (BOGI trial): a single-arm, multicenter, phase II trial. Blood. 2023;142(Supplement 1):3179–3179. doi:10.1182/blood-2023-174594
   Google Scholar
• Castagnetti F, Bocchia M, Abruzzese E, et al. Bosutinib dose optimization in the second-line treatment of elderly CML patients: extended 3-year follow-up and final results of the BEST study. HemaSphere. 2022;6:593–594. doi:10.1097/01.HS9.0000845676.81208.c2
   Google Scholar
• Isfort S, Manz K, Teichmann LL, et al. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the bosutinib dose optimization (BODO) study. Ann Hematol. 2023;102(10):2741–2752. doi:10.1007/s00277-023-05394-0
   PubMed Web of Science ®Google Scholar
• Brummendorf TH, Gambacorti-Passerini C, Hochhaus A, et al. Efficacy and safety following dose reduction of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia: analysis of the phase 3 BFORE trial. Blood. 2018;132(Supplement 1):3005–3005. doi:10.1182/blood-2018-99-110543
   Google Scholar
• Faber E, Divoká M, Skoumalová I, et al. A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Leuk Lymphoma. 2016;57(2):370–375. doi:10.3109/10428194.2015.1056184
   PubMed Web of Science ®Google Scholar
• Low dose dasatinib (50 mg Daily) as first-line treatment for newly diagnosed chronic-phase chronic myeloid leukemia. ClinicalTrials.gov Identifier NCT03625388 [updated 2023 Sep 22; cited 2023 Sep 23]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03625388?term=low+dose+dasatinib&cond=CML&draw=2&rank=2
   Google Scholar
• Iurlo A, Nobili A, Latagliata R, et al. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget. 2016;7(48):80083–80090. doi:10.18632/oncotarget.11657
   PubMedGoogle Scholar
• Haouala A, Widmer N, Duchosal MA, et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):e75–e87. doi:10.1182/blood-2010-07-294330
   PubMed Web of Science ®Google Scholar
• Wilkes JJ, Lyman GH, Doody DR, et al. Health care cost associated with contemporary chronic myelogenous leukemia therapy compared with that of other hematologic malignancies. J Clin Oncol Oncol Pract. 2021;17(3):e406–e415. doi:10.1200/OP.20.00143
   PubMedGoogle Scholar
• Chen Y, Xu N, Yang Y, et al. Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia. Cancer Med. 2023;12(16):17239–17252. doi:10.1002/cam4.6296
   PubMedGoogle Scholar
• Kenzik KM, Bhatia R, Williams GR, et al. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. Cancer. 2019;125(15):2570–2578. doi:10.1002/cncr.32137
   PubMed Web of Science ®Google Scholar
• Clark SE, Marcum ZA, Radich JP, et al. Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia. J Oncol Pharm Pract. 2021;27(8):1842–1852. doi:10.1177/1078155220970616
   PubMed Web of Science ®Google Scholar
• Campbell D, Blazer M, Bloudek L, et al. Realized and projected cost-savings from the introduction of generic imatinib through formulary management in patients with chronic myelogenous leukemia. Am Health Drug Benefits. 2019;12(7):333–342.
   PubMed Web of Science ®Google Scholar
• Yamamoto C, Nakashima H, Ikeda T, et al. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation. Blood Adv. 2019;3(21):3266–3277. doi:10.1182/bloodadvances.2019000745
   PubMed Web of Science ®Google Scholar
• Padula WV, Larson RA, Dusetzina SB, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016;108(7):djw003. doi:10.1093/jnci/djw003.
   PubMedGoogle Scholar
• Shih YT, Cortes JE, Kantarjian HM. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019;6(8):e398–e408. doi:10.1016/S2352-3026(19)30087-0
   PubMed Web of Science ®Google Scholar
• Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–311. doi:10.1200/JCO.2013.52.9123
   PubMed Web of Science ®Google Scholar
• Walia A, Prasad V. Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm. Blood Cancer J. 2023;13(1):36. doi:10.1038/s41408-023-00811-z
   PubMed Web of Science ®Google Scholar
• Kim Y, Go T-H, Jang J, et al. Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia. Korean J Intern Med. 2021;36(6):1450–1458. doi:10.3904/kjim.2021.158
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Rosti G, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107(6):904–909. doi:10.1038/bjc.2012.348
   PubMed Web of Science ®Google Scholar
• Zhang WW, Cortes JE, Yao H, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009;27(22):3642–3649. doi:10.1200/JCO.2008.19.4076
   PubMed Web of Science ®Google Scholar
• Senapati J, Sasaki K, Issa GC, et al. Management of chronic myeloid leukemia in 2023 – common ground and common sense. Blood Cancer J. 2023;13(1):58. doi:10.1038/s41408-023-00823-9
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2021;107(5):1045–1053. doi:10.3324/haematol.2021.279189
   Web of Science ®Google Scholar